Published: May 27, 2021 By Alex Keown
Singapore-based Esco Lifesciences closed a
$200 million oversubscribed Series A financing and crossover round that will enable the company that provides life sciences tools and services to expand its toehold in China and the United States.
Esco is a manufacturer of laboratory and biopharma equipment and IVF medical devices. The company has four different divisions, Scientific, Medical, Healthcare, and Aster, which offers “mission-critical equipment and advanced solutions” to laboratories, clinics, and bio-pharma production sites in over 100 countries.
The company employs more than 1,300 people across the globe. It has offices in more than 100 companies, including eight manufacturing and R&D hubs in the US, Europe, the UK, China, and Singapore. The financing round is the largest private fundraising round by an Asia-based life sciences tools company, Esco said in its announcement.